Cross Country Healthcare (CCRN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.39 per share a year ago.
Healthcare staffing companies saw a massive increase in revenues and profits following the Covid-19 pandemic. In the past year, that trend has reversed as hospitals shore up their staffing needs. CCRN stock is down almost 50% in 2024 as a result. CCRN has a strong balance sheet and a market cap so low that it trades below book value.
Investors need to pay close attention to Cross Country Healthcare (CCRN) stock based on the movements in the options market lately.
Cross Country Healthcare, Inc. (NASDAQ:CCRN ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Joshua Vogel - VP of IR John Martins - President and CEO Bill Burns - CFO Marc Krug - Group President of Delivery Conference Call Participants Kevin Fischbeck - Bank of America Trevor Romeo - William Blair Brian Tanquilut - Jefferies A.J. Rice - UBS Bill Sutherland - The Benchmark Company Tobey Sommer - Truist Constantine Davides - JMP Kevin Steinke - Barrington Research Operator Good afternoon, everyone.
While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cross Country Healthcare (CCRN) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.69 per share a year ago.
Investors are still hanging onto the momentum of some sectors in the stock market today, namely those in the technology sector dealing with the global adoption of artificial intelligence. However, some in the market feel like better opportunities in other areas are beginning to gain more bullish momentum, a rotation with a high acceptance rate.
Will the market get interest rate cuts at all this year? That is the question that looms over most investors' shoulders today.